Eisai Inc.
526
11
34
398
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.6%
77 terminated/withdrawn out of 526 trials
83.8%
-2.8% vs industry average
26%
137 trials in Phase 3/4
65%
257 of 398 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (526)
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Role: collaborator
A Study of Oral E1018 in Healthy Adult Participants
Role: lead
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Role: collaborator
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Role: collaborator
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Role: collaborator
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Role: collaborator
A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease
Role: lead
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Role: collaborator
DORA and LP in Alzheimer's Disease Biomarkers
Role: collaborator
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Role: lead
An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
Role: lead
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Role: collaborator
Merck IIT: RRP Pembro and Lenvatinib
Role: collaborator
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Role: collaborator
Scalp Cooling in MBC
Role: collaborator
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Role: collaborator
Study of E7386 in Participants With Selected Advanced Neoplasms
Role: lead
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Role: lead
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Role: lead
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Role: collaborator